Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

3.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.2K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.6K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

7.0K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
7.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Crossover Experiments01:16

Crossover Experiments

2.9K
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Random effect restricted mean survival time model.

Journal of biopharmaceutical statistics·2026
Same author

Platform trial of smartphone-based cognitive-behavioural therapy (CBT) for depressive symptoms among people with no or subthreshold depression: a protocol for the Best, Efficient and Affordable Training in Resilience in Constant Evolution (BEATRICE) platform trial.

BMJ open·2026
Same author

Sample Size Re-Estimation in Blinded Hybrid-Control Design Using Inverse Probability Weighting.

Statistics in medicine·2026
Same author

Multi-armed bandits backfill Bayesian optimal interval design.

Journal of biopharmaceutical statistics·2025
Same author

DBMS: dynamic borrowing method for frequentist hybrid control designs based on historical-current data similarity.

The international journal of biostatistics·2025
Same author

Adjusting confidence intervals under covariate-adaptive randomization in non-inferiority and equivalence trials.

Contemporary clinical trials·2025
Same journal

The sequential cohort randomized clinical trial: A study design for community-engaged clinical research in a rural American Indian community.

Contemporary clinical trials·2026
Same journal

Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression.

Contemporary clinical trials·2026
Same journal

Effectiveness of clinical trial recruitment strategies in a safety-net hospital.

Contemporary clinical trials·2026
Same journal

Are older adult research participants representative of the general population? Results from 19 clinical studies at one academic research center.

Contemporary clinical trials·2026
Same journal

Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD Caregiver Oncology Needs Evaluation Tool (CONNECT) trial.

Contemporary clinical trials·2026
Same journal

Rationale and design of a CArdiac rehabilitation program on the prevention of CardioTOXicity in breast Cancer patients undergoing treatment with anthracyclines and/or trastuzumab (CARPTOX-BC) trial: A randomized, active control group, open-label trial.

Contemporary clinical trials·2026
See all related articles

Related Experiment Video

Updated: Jul 26, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Data-dependent contrast test for dose-finding clinical trials.

Masahiro Kojima1

  • 1Biometrics Department, R&D Division, Kyowa Kirin Co., Ltd. Otemachi Financial City Grand Cube, 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-004, Japan; Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tokyo, Japan.

Contemporary Clinical Trials
|June 12, 2023
PubMed
Summary
This summary is machine-generated.

A novel data-dependent contrast test accurately identifies optimal drug doses. This powerful method, using ordinal-constraint coefficients, enhances dose-finding clinical trials by reliably determining dose-response relationships.

Keywords:
Contrast testDose-finding clinical trialDose-response relationship

More Related Videos

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K

Related Experiment Videos

Last Updated: Jul 26, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

15.8K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.3K

Area of Science:

  • Biostatistics
  • Clinical Pharmacology
  • Drug Development

Background:

  • Dose-finding studies are crucial for determining optimal therapeutic dosages.
  • Existing methods may lack power or flexibility in identifying dose-response relationships.
  • A robust statistical approach is needed for precise dose selection.

Purpose of the Study:

  • To introduce a data-dependent contrast test for dose-response assessment.
  • To establish a method for selecting the best dose-response model and identifying a recommended dose.
  • To evaluate the performance of the proposed test in various scenarios.

Main Methods:

  • Utilizing ordinal-constraint contrast coefficients calculated via the pool-adjacent-violators algorithm.
  • Implementing a data-dependent contrast test to determine dose-response significance (p < 0.05).
  • Comparing the proposed test against conventional methods and modeling techniques through simulation studies.

Main Results:

  • The data-dependent contrast test successfully confirmed dose-response relationships in sample and actual study data.
  • The test demonstrated greater power than conventional methods on datasets without a dose-response.
  • Type-1 error rates were maintained at significant levels even without treatment group differences.

Conclusions:

  • The data-dependent contrast test is a powerful and reliable tool for dose-finding clinical trials.
  • The method effectively identifies dose-response relationships and recommends optimal doses.
  • It offers a robust alternative to existing statistical approaches in clinical pharmacology.